Early on in the pandemic, the International Federation of Pharmaceutical Manufacturers & Associations laid out seven commitments to communicate, guide, and measure our work in the fight against COVID-19.

A definitive analysis of our efforts will be possible only when the pandemic is over. However, the significant efforts and associated learnings accumulated since early 2020 enable meaningful early insights to inform the current crisis and the future course.

This report identifies 10 insights the biopharmaceutical industry has gathered so far as the world moves into the third year of the COVID-19 pandemic.

We present them as hard-learned lessons to date – and as urgent strategies to end this pandemic and better prepare for the next one.

10 insights gathered by the biopharmaceutical industry

• Health security starts with pathogen surveillance and sharing
• Partnerships accelerate R&D and manufacturing
• Advance market commitments support manufacturing scale-up for global pandemic response
• Innovation is essential for preparedness and response
• Global upstream supply chains disruptions put production and distribution at risk
• An established procurement mechanism for low-income countries is vital
• Regulatory agility and convergence guard safety and speed of access
• Vaccine nationalism imperils everyone
• Delivery infrastructure must be strengthened
• Vaccine confidence is critical for success